NEW YORK (GenomeWeb News) – Investment firm ISI Group on Wednesday downgraded shares of Hologic, saying the company's new management will need time to turn the business around.

ISI downgraded Hologic's shares to Buy from a previous Strong Buy rating, but maintained earlier EPS estimates of $1.35 for Fiscal Year 2014; $1.55 for FY 2015; and $1.75 for FY 2016.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.